Skip to content
2000
Volume 25, Issue 7
  • ISSN: 1566-5240
  • E-ISSN: 1875-5666

Abstract

Objective

Primary Aldosteronism (PA) is the most common cause of secondary hypertension. Immunohistochemical analysis of PA is based on specific monoclonal antibodies targeting CYP11B1 and CYP11B2, which are enzymes responsible for the aldosterone production in the adrenal cortex. The recently proposed HISTALDO classification introduced CYP11B2 immunohistochemistry to define clinically relevant diagnostic categories. We aimed to investigate the relationship between clinical characteristics and immunohistochemistry of CYP11B2 in PA and also evaluate staining in cortisol-producing cells by comparing patients with Cushing’s Syndrome (CS). Consecutive patients diagnosed with PA (n=21) and CS (n=20) were included between 2015-2022. All of them underwent unilateral adrenalectomy in our tertiary center.

Methods

Following hematoxylin and eosin (H&E) staining of the pathological specimens, all slides were re-evaluated and immunostained for CYP11B2. A semiquantitative H-score was assessed for each patient and compared with staining intensity. Patients with PA were grouped and classified according to the HISTALDO classification.

Results

The mean size of adenoma in patients with PA was much smaller compared to patients with CS (p=0.001). An increase in the immunohistochemical H-score of the patients with PA (121.36 ±81.04 vs 73.94±57.70, p=0.045) was observed in comparison to the patients with CS. When comparing the patients with PA according to HISTALDO criteria, the H-score of the patients with Aldosterone Producing Adenoma (APA, n=10) was 136.6±78.86 compared to the non-APA group, which was 86.81±85.3 (n=11, p=0.05). Moreover, mean preoperative aldosterone levels (p=0.06) and aldosterone-to-renin ratio (ARR, p=0.03) were higher in patients with APA compared to non-APA patients. Response to surgical therapy was more favorable in patients with APA than the patients with non-APA.

Conclusion

CYP11B2 is a key enzyme responsible for the synthesis of aldosterone. CYP11B2 expression, as assessed by immunostaining, was associated with the clinical characteristics, severity of PA, and response to the treatment. Hence, immunohistochemical analysis of CYP11B2 should be incorporated into the routine clinical workup to better localize aldosterone-producing cells.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmm/10.2174/0115665240378395250416064732
2025-05-02
2025-12-17

  • From This Site

    /content/journals/cmm/10.2174/0115665240378395250416064732
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ZennaroM.C. BoulkrounS. Fernandes-RosaF.L. Pathogenesis and treatment of primary aldosteronism.Nat. Rev. Endocrinol.2020161057858910.1038/s41574‑020‑0382‑4 32724183
     [Google Scholar]
  2. St-JeanM. BourdeauI. MartinM. LacroixA. Aldosterone is aberrantly regulated by various stimuli in a high proportion of patients with primary aldosteronism.J. Clin. Endocrinol. Metab.20211061e45e6010.1210/clinem/dgaa703 33000146
     [Google Scholar]
  3. MonticoneS. BurrelloJ. TizzaniD. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice.J. Am. Coll. Cardiol.201769141811182010.1016/j.jacc.2017.01.052 28385310
     [Google Scholar]
  4. AhnC.H. NaH.Y. ParkS.Y. Expression of CYP11B1 and CYP11B2 in adrenal adenoma correlates with clinical characteristics of primary aldosteronism.Clin. Endocrinol. (Oxf.)2022961303910.1111/cen.14628 34743356
     [Google Scholar]
  5. NakamuraY. KitadaM. SatohF. Intratumoral heterogeneity of steroidogenesis in aldosterone-producing adenoma revealed by intensive double- and triple-immunostaining for CYP11B2/B1 and CYP17.Mol. Cell. Endocrinol.2016422576310.1016/j.mce.2015.11.014 26597777
     [Google Scholar]
  6. FalloF. PezziV. BarzonL. Quantitative assessment of CYP11B1 and CYP11B2 expression in aldosterone-producing adenomas.Eur. J. Endocrinol.2002147679580210.1530/eje.0.1470795 12457455
     [Google Scholar]
  7. MeteO. EricksonL.A. JuhlinC.C. Overview of the 2022 who classification of adrenal cortical tumors.Endocr. Pathol.202233115519610.1007/s12022‑022‑09710‑8 35288842
     [Google Scholar]
  8. FunderJ.W. CareyR.M. ManteroF. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline.J. Clin. Endocrinol. Metab.201610151889191610.1210/jc.2015‑4061 26934393
     [Google Scholar]
  9. WilliamsT.A. LendersJ.W.M. MulateroP. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort.Lancet Diabetes Endocrinol.20175968969910.1016/S2213‑8587(17)30135‑3 28576687
     [Google Scholar]
  10. IacoboneM. CittonM. VielG. Unilateral adrenal hyperplasia: A novel cause of surgically correctable primary hyperaldosteronism.Surgery201215261248125510.1016/j.surg.2012.08.042 23158191
     [Google Scholar]
  11. EnbergU. VolpeC. HöögA. Postoperative differentiation between unilateral adrenal adenoma and bilateral adrenal hyperplasia in primary aldosteronism by mRNA expression of the gene CYP11B2.Eur. J. Endocrinol.20041511738510.1530/eje.0.1510073 15248825
     [Google Scholar]
  12. WilliamsT.A. Gomez-SanchezC.E. RaineyW.E. International histopathology consensus for unilateral primary aldosteronism.J. Clin. Endocrinol. Metab.20211061425410.1210/clinem/dgaa484 32717746
     [Google Scholar]
  13. AbeT. NaruseM. YoungW.F.Jr A novel CYP11B2‐specific imaging agent for detection of unilateral subtypes of primary aldosteronism.J. Clin. Endocrinol. Metab.201610131008101510.1210/jc.2015‑3431 26756116
     [Google Scholar]
  14. Gomez-SanchezC.E. QiX. Velarde-MirandaC. Development of monoclonal antibodies against human CYP11B1 and CYP11B2.Mol. Cell. Endocrinol.20143831-211111710.1016/j.mce.2013.11.022 24325867
     [Google Scholar]
  15. NishimotoK. NakagawaK. LiD. Adrenocortical zonation in humans under normal and pathological conditions.J. Clin. Endocrinol. Metab.20109552296230510.1210/jc.2009‑2010 20200334
     [Google Scholar]
  16. NanbaK. TsuikiM. SawaiK. Histopathological diagnosis of primary aldosteronism using CYP11B2 immunohistochemistry.J. Clin. Endocrinol. Metab.20139841567157410.1210/jc.2012‑3726 23443813
     [Google Scholar]
  17. NakamuraY. MaekawaT. FelizolaS.J.A. Adrenal CYP11B1/2 expression in primary aldosteronism: Immunohistochemical analysis using novel monoclonal antibodies.Mol. Cell. Endocrinol.20143921-2737910.1016/j.mce.2014.05.002 24837548
     [Google Scholar]
  18. MonticoneS. CastellanoI. VersaceK. Immuno-histochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas.Mol. Cell. Endocrinol.201541114615410.1016/j.mce.2015.04.022 25958045
     [Google Scholar]
  19. DekkersT. ter MeerM. LendersJ.W.M. Adrenal nodularity and somatic mutations in primary aldosteronism: one node is the culprit?J. Clin. Endocrinol. Metab.2014997E1341E135110.1210/jc.2013‑4255 24758183
     [Google Scholar]
/content/journals/cmm/10.2174/0115665240378395250416064732
Loading
Immunohistochemical Analysis of CYP11B2 (Aldosterone Synthase) and Evaluation of the HISTALDO Classification in Patients with Primary Aldosteronism
Current Molecular Medicine 25, 927 (2025); https://doi.org/10.2174/0115665240378395250416064732
/content/journals/cmm/10.2174/0115665240378395250416064732
/content/journals/cmm/10.2174/0115665240378395250416064732
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): CYP11B2 enzyme activity; HISTALDO classification; hypertension; hypokalemia; immunohistochemistry; primary hyperaldosteronism

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test